The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles

Biomaterials

Volumn 35, Issue 9, 2014, Pages 3044-3051

  Tan, Guang Rong ^a   Feng, Si Shen ^a   Leong, David T ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anti cancer drug; Biodegradable polymer; Cancer nanotechnology; Combination therapy; Drug antagonism; Nanomedicine

Indexed keywords

BIODEGRADABLE POLYMERS; CELL CULTURE; DISEASES; DRUG INTERACTIONS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TARGETED DRUG DELIVERY;

ANTICANCER DRUG; BREAST CANCER; CANCER NANOTECHNOLOGY; CELLULAR UPTAKE; COMBINATION THERAPY; DRUG ANTAGONISM; DRUG CONCENTRATION; NANOPARTICLE (NPS);

CONTROLLED DRUG DELIVERY;

COUMARIN; DOCETAXEL; POLY(LACTIDE) DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; POLYLACTIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RELEASE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; PRIORITY JOURNAL;

ANTI-CANCER DRUG; BIODEGRADABLE POLYMER; CANCER NANOTECHNOLOGY; COMBINATION THERAPY; DRUG ANTAGONISM; NANOMEDICINE;

ANTINEOPLASTIC AGENTS; CELL DEATH; COLLOIDS; COUMARINS; DRUG ANTAGONISM; ENDOCYTOSIS; HUMANS; MCF-7 CELLS; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; VITAMIN E;

EID: 84895002084     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.033     Document Type: Article

References (56)

1. Grayson M. Breast cancer. Nature 2012, 485:S49.
2. Maxmen A. The hard facts. Nature 2012, 485. S50-51.
3. Von Minckwitz G., Costa S.D., Raab G., Blohmer J.U., Eidtmann H., Hilfrich J., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001, 19:3506-3515.
4. Scripture C.D., Figg W.D. Drug interactions in cancer therapy. Nat Rev Cancer 2006, 6:546-558.
5. Undevia S.D., Gomez-Abuin G., Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5:447-458.
6. Hirth J., Watkins P.B., Strawderman M., Schott A., Bruno R., Baker L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000, 6:1255-1258.
7. Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009, 9:576-586.
8. Michor F., Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res 2010, 3:1361-1364.
9. Leong D.T., Lim J., Goh X., Pratap J., Pereira B.P., Kwok H.S., et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 2010, 12:R89.
10. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
11. Decker S., Sausville E.A. Preclinical modeling of combination treatments: fantasy or requirementα. Ann N Y Acad Sci 2005, 1059:61-69.
12. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
13. Rougier P., Lepère C. Metastatic colorectal cancer: first- and second-line treatment in 2005. Semin Oncol 2005, 32(Suppl.):15-20.
14. Ferlini C., Scambia G., Distefano M., Filippini P., Isola G., Riva A., et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997, 75:884-891.
15. Ikeda H., Taira N., Nogami T., Shien K., Okada M., Shien T., et al. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci 2011, 102:2038-2042.
16. Harasym T.O., Liboiron B.D., Mayer L.D. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol 2010, 596:291-323.
17. Tardi P.G., Dos Santos N., Harasym T.O., Johnstone S.A., Zisman N., Tsang A.W., et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009, 8:2266-2275.
18. Dicko A., Mayer L.D., Tardi P.G. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv 2010, 7:1329-1341.
19. Setyawati M.I., Tay C.Y., Chia S.L., Goh S.L., Fang W., Neo M.J., et al. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat Commun 2013, 4:1673.
20. Setyawati M.I., Tay C.Y., Leong D.T. Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway. Biomaterials 2013, 34:10133-10142.
21. Ng K.W., Khoo S.P.K., Heng B.C., Setyawati M.I., Tan E.C., Zhao X., et al. The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles. Biomaterials 2011, 32:8218-8225.
22. Zhang X.-D., Chen J., Min Y., Park G.B., Shen X., Song S.-S., et al. Metabolizable Bi 2 Se 3 nanoplates: biodistribution, toxicity, and uses for cancer radiation therapy and imaging. Adv Funct Mater 2013, doi:10.1002/adfm.201302312.
23. Tay C.Y., Cai P.Q., Setyawati M.I., Fang W., Tan L.P., Hong C.H.L., et al. Nanoparticles strengthen intracellular tension and retard cellular migration. Nano Lett 2013, doi:10.1021/nl4032549.
24. Zhang X.-D., Chen J., Luo Z., Wu D., Shen X., Song S.-S., et al. Enhanced tumor accumulation of sub-2 nm gold nanoclusters for cancer radiation therapy. Adv Healthc Mater 2013, doi:10.1002/adhm.201300189.
25. Tay C.Y., Fang W., Setyawati M.I., Sum C.P., Xie J., Ng K.W., et al. Reciprocal response of human oral epithelial cells to internalized silica nanoparticles. Part Part Syst Charact 2013, 30:784-793.
26. Zhang W., Meng J., Ji Y., Li X., Kong H., Wu X., et al. Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system. Nanoscale 2011, 3:3923-3932.
27. Zhang W., Liu J., Tabata Y., Meng J., Xu H. The effect of serum in culture on RNAi efficacy through modulation of polyplexes size. Biomaterials 2014, 35:567-577.
28. Hu F.X., Neoh K.G., Kang E.T. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006, 27:5725-5733.
29. Jain A.K., Swarnakar N.K., Godugu C., Singh R.P., Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503-515.
30. Ma Y., Zheng Y., Zeng X., Jiang L., Chen H., Liu R., et al. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int J Nanomedicine 2011, 6:2679-2688.
31. Jones S. Docetaxel-loaded nanoparticles shrink human tumors. Nat Biotechnol 2012, 30:411.
32. Ling Y., Wei K., Luo Y., Gao X., Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32:7139-7150.
33. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226-232.
34. Zheng C., Zheng M., Gong P., Deng J., Yi H., Zhang P., et al. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials 2013, 34:3431-3438.
35. Xu Z., Zhang Z., Chen Y., Chen L., Lin L., Li Y. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials 2010, 31:916-922.
36. Shi J., Zhang H., Wang L., Li L., Wang H., Wang Z., et al. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials 2013, 34:251-261.
37. Li Y., He H., Jia X., Lu W.-L., Lou J., Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 2012, 33:3899-3908.
38. Jain A.K., Thanki K., Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharm 2013, 10:3459-3474.
39. Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005, 6:229-239.
40. Collins R., Trowman R., Norman G., Light K., Birtle A., Fenwick E., et al. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer 2006, 95:457-462.
41. Allen K.E., Clark E.R., Jordan V.C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 1980, 71:83-91.
42. Jordan V.C., Collins M.M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977, 75:305-316.
43. Sparreboom A., Van Tellingen O., Scherrenburg E.J., Boesen J.J., Huizing M.T., Nooijen W.J., et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996, 24:655-658.
44. Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005, 44:279-304.
45. Zhao X.-J., Jones D.R., Wang Y.-H., Grimm S.W., Hall S.D. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002, 32:863-878.
46. Zhang Z., Feng S.S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006, 27:4025-4033.
47. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16:1550-1556.
48. Mi Y., Liu Y., Feng S.-S. Formulation of docetaxel by folic acid-conjugated D-α-tocopheryl polyethylene glycol succinate 2000 (vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
49. Zhang Z.P., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
50. Prashant C., Dipak M., Yang C.T., Chuang K.H., Jun D., Feng S.S. Superparamagnetic iron oxide-loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials 2010, 31:5588-5597.
51. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
52. Aryal S., Hu C.-M., Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 2011, 8:1401-1407.
53. Bourzac K. Nanotechnology: carrying drugs. Nature 2012, 491:S58-S60.
54. Zhang Y., Tran R.T., Qattan I.S., Tsai Y.-T., Tang L., Liu C., et al. Fluorescence imaging enabled urethane-doped citrate-based biodegradable elastomers. Biomaterials 2013, 34:4048-4056.
55. Ikeda H., Taira N., Hara F., Fujita T., Yamamoto H., Soh J., et al. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 2010, 12:R43.
56. El-Kareh A.W., Secomb T.W. Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia 2005, 7:705-713.